Dr. Chamindra Konersman, MD
Claim this profileRady Children's Hospital San Diego
Affiliated Hospitals
Rady Children's Hospital - San Diego
UC San Diego Altman Clinical And Translational Research Institute
Clinical Trials Chamindra Konersman, MD is currently running
Zolgensma
for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
Recruiting
1 award
N/A
2 criteria
Biomarkers
for Myotonic Dystrophy
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward. Funding Source- FDA OOPD
Recruiting
1 award
N/A
4 criteria
More about Chamindra Konersman, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Chamindra Konersman, MD has experience with
- Prospective Observational Registry
- Zolgensma
- Placebo
- SRP-9001 (Delandistrogene Moxeparvovec)
- No Investigational New Treatment
- Establishing Biomarkers And Clinical Endpoints
Breakdown of trials Chamindra Konersman, MD has run
Myelodysplastic Syndrome
Muscular Dystrophy
Spinal Muscular Atrophy
Duchenne Muscular Dystrophy
Limb-Girdle Muscular Dystrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chamindra Konersman, MD specialize in?
Chamindra Konersman, MD focuses on Myelodysplastic Syndrome and Muscular Dystrophy. In particular, much of their work with Myelodysplastic Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Chamindra Konersman, MD currently recruiting for clinical trials?
Yes, Chamindra Konersman, MD is currently recruiting for 2 clinical trials in San Diego California. If you're interested in participating, you should apply.
Are there any treatments that Chamindra Konersman, MD has studied deeply?
Yes, Chamindra Konersman, MD has studied treatments such as Prospective observational registry, Zolgensma, Placebo.
What is the best way to schedule an appointment with Chamindra Konersman, MD?
Apply for one of the trials that Chamindra Konersman, MD is conducting.
What is the office address of Chamindra Konersman, MD?
The office of Chamindra Konersman, MD is located at: Rady Children's Hospital San Diego, San Diego, California 92123 United States. This is the address for their practice at the Rady Children's Hospital San Diego.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.